دورية أكاديمية
أعرض في EDS

Quantitative Evaluation of Type 1 and Type 2 Choroidal Neovascularization Components Under Treatment With Projection-Resolved OCT Angiography.

التفاصيل البيبلوغرافية
العنوان: Quantitative Evaluation of Type 1 and Type 2 Choroidal Neovascularization Components Under Treatment With Projection-Resolved OCT Angiography.
المؤلفون: Tsuboi K; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.; Department of Ophthalmology, Aichi Medical University, Nagakute, Japan., You QS; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States., Wang J; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States., Guo Y; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States., Flaxel CJ; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States., Hwang TS; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States., Huang D; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States., Jia Y; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States., Bailey ST; Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
المصدر: Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2024 Sep 03; Vol. 65 (11), pp. 32.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Association For Research In Vision And Ophthalmology (Arvo) Country of Publication: United States NLM ID: 7703701 Publication Model: Print Cited Medium: Internet ISSN: 1552-5783 (Electronic) Linking ISSN: 01460404 NLM ISO Abbreviation: Invest Ophthalmol Vis Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: Brookline Ma : Association For Research In Vision And Ophthalmology (Arvo)
Original Publication: St. Louis, Mosby.
مواضيع طبية MeSH: Tomography, Optical Coherence*/methods , Fluorescein Angiography*/methods , Angiogenesis Inhibitors*/therapeutic use , Intravitreal Injections* , Choroidal Neovascularization*/drug therapy , Choroidal Neovascularization*/diagnostic imaging , Choroidal Neovascularization*/diagnosis , Vascular Endothelial Growth Factor A*/antagonists & inhibitors, Humans ; Retrospective Studies ; Male ; Female ; Aged ; Aged, 80 and over ; Visual Acuity ; Ranibizumab/therapeutic use ; Ranibizumab/administration & dosage ; Wet Macular Degeneration/drug therapy ; Wet Macular Degeneration/diagnosis ; Fundus Oculi ; Follow-Up Studies ; Undertreatment
مستخلص: Purpose: To evaluate the response of type 1 and type 2 macular neovascularization (MNV) components under anti-vascular endothelial growth factor (VEGF) treatment in age-related macular degeneration (AMD) using projection-resolved optical coherence tomography angiography (PR-OCTA).
Methods: This retrospective study included eyes with treatment-naïve exudative AMD treated with anti-VEGF injections under a pro re nata (PRN) protocol over 1 year. Two-dimensional MNV areas and three-dimensional MNV volumes were derived from macular PR-OCTA scans using an automated convolutional neural network. MNV was detected as flow signal within the outer retinal slab. Type 1 components and type 2 components were analyzed separately.
Results: Of 17 enrolled eyes, 12 eyes were pure type 1 MNV and five eyes were type 2 MNV. In eyes with pure type 1, the total (sum of type 1 and type 2 components) MNV area and volume did not change from baseline to 6 months or 12 months (P > 0.05). In eyes with type 2 MNV, the total MNV area significantly decreased from the baseline to 6 months (P = 0.0074) and 12 months (P = 0.014). The total type 2 MNV volume also decreased from baseline visit to visits at 6 months and at 12 months, nearing statistical signifiicance (P = 0.061 and P = 0.074). In eyes with type 2 MNV, the type 1 component increased from 0.093 mm2 to 0.30 mm2 (P = 0.058), and the type 2 component decreased from 0.37 mm2 at 6 months to 0 at 12 months (P = 0.0087).
Conclusions: Type 1 and type 2 MNV may have different response under PRN anti-VEGF treatment over 1 year.
References: Retina. 2010 Oct;30(9):1333-49. (PMID: 20924258)
N Engl J Med. 2006 Oct 5;355(14):1474-85. (PMID: 17021323)
Am J Ophthalmol. 1998 Jul;126(1):70-6. (PMID: 9683151)
Am J Ophthalmol. 2015 Oct;160(4):739-48.e2. (PMID: 26164826)
Transl Vis Sci Technol. 2020 Jul 07;9(8):8. (PMID: 32855855)
N Engl J Med. 2008 Jun 12;358(24):2606-17. (PMID: 18550876)
Arch Ophthalmol. 1980 May;98(5):832. (PMID: 6155116)
Surv Ophthalmol. 2003 May-Jun;48(3):257-93. (PMID: 12745003)
J Ophthalmol. 2018 Feb 04;2018:3751702. (PMID: 29507810)
Biomed Opt Express. 2015 Aug 25;6(9):3564-76. (PMID: 26417524)
Ophthalmology. 1996 Aug;103(8):1260-70. (PMID: 8764797)
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4285-4291. (PMID: 30372757)
Am J Ophthalmol. 2014 Oct;158(4):769-779.e2. (PMID: 25034111)
Retina. 2017 Feb;37(2):222-233. (PMID: 27627752)
Retina. 2012 Jun;32(6):1069-76. (PMID: 22466476)
Ophthalmol Retina. 2019 Aug;3(8):629-636. (PMID: 31068262)
Am J Ophthalmol. 1994 Sep 15;118(3):285-98. (PMID: 7521987)
Am J Ophthalmol. 2015 Jul;160(1):6-16. (PMID: 25887628)
Int J Retina Vitreous. 2020 Aug 20;6:39. (PMID: 32844038)
Semin Ophthalmol. 2019;34(3):168-176. (PMID: 31132283)
Biomed Opt Express. 2017 Feb 15;8(3):1536-1548. (PMID: 28663848)
Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2395-402. (PMID: 25897021)
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1944-1952. (PMID: 29677356)
Eye (Lond). 2015 Jul;29(7):932-5. (PMID: 25976641)
Invest Ophthalmol Vis Sci. 1986 Nov;27(11):1644-52. (PMID: 2429937)
Biomed Opt Express. 2015 Nov 02;6(12):4661-75. (PMID: 26713185)
Am J Ophthalmol. 2022 May;237:164-172. (PMID: 34942107)
Ophthalmol Retina. 2019 Oct;3(10):835-842. (PMID: 31257069)
Retina. 2023 Mar 1;43(3):412-419. (PMID: 36730570)
Am J Ophthalmol. 2004 Mar;137(3):496-503. (PMID: 15013874)
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1671-6. (PMID: 19875667)
Biomed Opt Express. 2020 Jan 14;11(2):927-944. (PMID: 32133230)
Br J Ophthalmol. 2007 Sep;91(9):1173-6. (PMID: 17383997)
Biomed Opt Express. 2016 Feb 09;7(3):816-28. (PMID: 27231591)
Graefes Arch Clin Exp Ophthalmol. 1994 Jun;232(6):361-7. (PMID: 8082844)
Am J Ophthalmol. 2012 Feb;153(2):314-9. (PMID: 21982958)
Retina. 2018 Feb;38(2):220-230. (PMID: 28582276)
Retina. 2015 Nov;35(11):2219-28. (PMID: 26398697)
Ophthalmol Retina. 2018 Sep;2(9):931-941. (PMID: 30238069)
PLoS One. 2019 Apr 29;14(4):e0216304. (PMID: 31034505)
Ophthalmology. 2014 Jul;121(7):1435-44. (PMID: 24679442)
معلومات مُعتمدة: P30 EY010572 United States EY NEI NIH HHS; R01 EY024544 United States EY NEI NIH HHS; R01 EY027833 United States EY NEI NIH HHS
المشرفين على المادة: 0 (Angiogenesis Inhibitors)
0 (Vascular Endothelial Growth Factor A)
ZL1R02VT79 (Ranibizumab)
تواريخ الأحداث: Date Created: 20240920 Date Completed: 20240920 Latest Revision: 20240926
رمز التحديث: 20240926
مُعرف محوري في PubMed: PMC11421666
DOI: 10.1167/iovs.65.11.32
PMID: 39302645
قاعدة البيانات: MEDLINE
الوصف
تدمد:1552-5783
DOI:10.1167/iovs.65.11.32